Health Dictionary Find a Doctor

Multiple sclerosis

For patient information click here

Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1]; Associate Editor(s)-in-Chief: Fahimeh Shojaei, M.D.

Synonyms and keywords: Disseminated sclerosis; encephalomyelitis disseminata; Ms; Demyelinating Autoimmune Disease; multipel sclerosis; multiple scelerosis; multipel scelerosis


Overview

Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1]; Associate Editor(s)-in-Chief: Fahimeh Shojaei, M.D.

Overview

Multiple sclerosis is a disease of the central nervous system and it’s known to be multi factorial. The most common risk factors in the development of multiple sclerosis are smoking, genetic, ethnic, infection, low vitamin D, and stress. Whatever the trigger is, it will lead to an acquired immune response followed by inflammatory reactions. These reactions lead to secretion of cytokines in the CNS parenchyma and activation of resident microglia. Microglia cells activate astrocytes to release more inflammatory cytokines, leading to recruitment and infiltration of circulatory leukocytes. This burst events cause destruction of myelin sheath and forms focal sclerotic white matter plaques, which are characteristic of multiple sclerotic disease. The onset of symptoms is mostly between the age of fifteen to forty years, rarely before age fifteen or after age sixty and include fatigue, mood problems, spasticity, bowel and bladder dysfunction, cognitive impairment, eye movement problems, heat sensitivity, incoordination, pain, sexual dysfunction, sleep disorder, vertigo and visual loss. There is no single diagnostic study of choice for the diagnosis of multiple sclerosis, but multiple sclerosis can be diagnosed based on clinical presentation, cerebral plaques on MRI , and oligoclonal bands in CSF analysis. The predominant therapy for multiple sclerosis is disease-modifying treatment in relapsing-remitting multiple sclerosis, immunosuppressive threpay in progressive multiple sclerosis and Glucocorticoid therapy in acute exacerbation.

Historical Perspective

Multiple sclerosis was first described by a neurologist, Dr. Jean Martin Charcot in 1868 and named sclerose en plaque. The signs and symptoms including dysarthria, ataxia and tremor were called charcot’s triad.

Classification

Multiple sclerosis may be classified into four groups according to clinical course of the disease including relapsing-remitting, secondary-progressive, primary-progressive and progressive-relapsing. other variants of Multiple sclerosis include clinically isolated syndrome and radiologically isolated syndrome.

Pathophysiology

Multiple sclerosis is a disease of the central nervous system and it’s known to be multi factorial. Whatever the trigger is, it will lead to an acquired immune response followed by inflammatory reactions. These reactions lead to secretion of cytokines in the CNS parenchyma and activation of resident microglia. Microglia cells activate astrocytes to release more inflammatory cytokines, leading to recruitment and infiltration of circulatory leukocytes. This burst events cause destruction of myelin sheath and forms focal sclerotic white matter plaques, which are characteristic of multiple sclerotic disease. There is some evidence proving genetic involvement in onset of MS so that it increases the risk of developing MS from 0.1% in general population to 3% in those who have siblings with MS and 25% in those with a mono-zygote twin affected. Based on studies performed on post mortem brain tissue of patients with multiple sclerosis, there are four types of white matter lesion pathology. Damage to myelin sheath is prominent in type 1 and 2 while type 3 and 4 characteristic is dying oligodendrocytes. the etiology of oligodendrocytes death known to be multi-factorial or followed by hypoxia, mitochondrial dysfunction and macrophages.

Causes

Multiple sclerosis may be caused by different categories of causes include: Autoimmunity, genetic, infectious and degeneration.

Differentiating Multiple Sclerosis from other Diseases

Multiple sclerosis must be differentiated from other diseases that can mimic this disease clinically or radiologically such as systemic lupus erythematosis, Sjögren’s syndrome, vasculitis, neuro-behçet’s disease, sarcoidosis, antiphospholipid (Hughes) syndrome , susac syndrome, lyme disease, syphilis, HTLV-1 infection, HIV-Related Disorders of the CNS, migraine, cerebral autosomal dominant arteriopathy with subcortical infarcts and leukoencephalopathy, leber’s hereditary optic neuropathy, vitamin B12 deficiency, metachromatic leukodystrophy, Fabry’s disease, Krabbe’s disease, adrenoleukodystrophy, mitochondrial encephalopathy epilepsy lactic acidosis and stroke like episode, stroke, primary CNS lymphoma , and dural arteriovenous fistula and true malformations.

Epidemiology and Demographics

The majority of multiple sclerosis cases are reported in northern Europe, continental North America, and Australasia, which is about one of every 1000 citizens. Factors including sunlight exposure, climate, diet, toxins, genetic factors, geomagnetism, Childhood environmental factors and infections have been proved to cause these differences in MS prevalence. MS is at least two times more common among women than men. The onset of symptoms is mostly between the age of fifteen to forty years, rarely before age fifteen or after age sixty.

Risk Factors

Common risk factors in the development of multiple sclerosis are smoking, genetic, ethnic, infection, low vitamin D, and stress. Less common risk factors in the development of multiple sclerosis include African Americans, Mexicans, Japanese, Chinese and Filipinos race and Epstein-Barr virus.

Natural History, Complications and Prognosis

Multiple sclerosis usually start between age of fifteen to forty years, rarely before age fifteen or after age sixty with symptoms such as optic neuritis, diplopia, sensory or motor loss, vertigo and balance problems. It may be classified into four groups according to clinical course of the disease including relapsing-remitting, secondary-progressive, primary-progressive, and progressive-relapsing. Complications that can develop as a result of multiple sclerosis are: medication complication, Fatigue, mood problems, Spasticity, Bowel and bladder dysfunction, Cognitive impairment, Heat sensitivity., Incoordination, Pain, Sexual dysfunction, Sleep disorders, vertigo, visual loss. there are some factors associated with a particularly poor prognosis among patients with multiple sclerosis such as: Relapsing versus progressive disease, early symptoms, Demographics, Sex, Smoking.

Diagnosis

Diagnostic Study of choice

There is no single diagnostic study of choice for the diagnosis of multiple sclerosis, but multiple sclerosis can be diagnosed based on clinical presentation, MRI findings, and CSF analysis. Sequence of diagnostic studies are history and physical examination, imaging, and CSF analysis. The findings are cerebral plaques which are demyelinating areas on MRI and an elevated concentration of CSF oligoclonal bands. The diagnostic criteria for multiple sclerosis is McDonald criteria.

History and Symptoms

The most common symptoms of multiple sclerosis include: Fatigue, mood problems, spasticity, bowel and bladder dysfunction, cognitive impairment, eye movement problems, heat sensitivity, incoordination, pain, sexual dysfunction, sleep disorder, vertigo and visual loss.

Physical Examination

Physical examination of patients with multiple sclerosis is usually remarkable for lhermitte’s sign, spasticity, increased reflexes, internuclear ophthalmoplegia, optic neuritis, gait disturbance, and urinary incontinence.

Laboratory Findings

An elevated concentration of CSF oligoclonal bands is diagnostic of multiple sclerosis.

Electrocardiogram

An ECG may be helpful in the diagnosis of multiple sclerosis. Findings on an ECG suggestive of multiple sclerosis include atrial fibrillation, ventricular arrhythmia, shortened or longed P-R interval, tall waves or peaked waves, U waves, and Q waves.

X-ray

There are no x-ray findings associated with multiple sclerosis.

Echocardiography and Ultrasound

There are no echocardiography/ultrasound findings associated with multiple sclerosis.

CT scan

Findings on CT scan suggestive of multiple sclerosis include brain atrophy and some contrast enhancing plaques. Findings on an Double delayed high dose CT scan suggestive of Multiple sclerosis include enhanced lesions in double delayed high dose CT scan which are indicators of blood brain barrier disruption.

MRI

On MRI, multiple sclerosis is characterized by cerebral plaques disseminating in space and time which are characteristic of demyelinating areas. These lesions are commonly void, and located in periventricular white matter, cerebellum, and the brain stem. These lesions are hyperintense on T2 sections of a MRI.

Other Imaging Findings

There is no other imaging findings associated with multiple sclerosis.

Other Diagnostic Studies

Visual evoked potential studies, antimyelin antibodies, and optimal coherence tomography may be helpful in the diagnosis of multiple sclerosis.

Treatment

Medical Therapy

The predominant therapy for multiple sclerosis is disease-modifying treatment in relapsing-remitting multiple sclerosis, immunosuppressive threpay in progressive multiple sclerosis and Glucocorticoid therapy in acute exacerbation.

Surgery

Surgery can be helpful in controlling trigeminal neuralgia, tremor, and ataxia.

Alternative Therapies

Alternative treatments for multiple sclerosis are: Dietary regimens herbal medicine ( marijuana ) hyperbaric oxygenation therapeutic practice of martial arts.

Primary Prevention

Effective measures for the primary prevention of multiple sclerosis include: Vitamin D supplement, smoking cessation, early exposure to infections.

Secondary Prevention

There is no established method for secondary prevention of multiple sclerosis.

Tertiary Prevention

Tertiary: There is strong evidence that exercise therapy can improve muscle function and mobility in multiple sclerosis patients.

References

Template:WH Template:WS

Historical Perspective

Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1]; Associate Editor(s)-in-Chief: Fahimeh Shojaei, M.D.,

Overview

Multiple sclerosis was first described by a neurologist, Dr. Jean Martin Charcot in 1868 and named sclerose en plaque. The signs and symptoms including dysarthria, ataxia, and tremor were called ‘Charcot’s triad‘.

Historical Perspective

Discovery

  • Multiple sclerosis was first described by a neurologist, Dr. Jean martin Charcot in 1868.
  • Previously, Dr. Robert Hooper (1773-1835), Robert Carswell (1793-1857), and Jean Cruveilhier (1791-1873) had noticed some of the MS clinical manifestations, but for the first time, Dr. Charcot described it as a distinct disease and named sclerose en plaque.
  • The signs and symptoms including dysarthria, ataxia, and tremor, were called charcot’s triad by Dr. Charcot for the first time.

Famous Cases

References

  1. Charcot, J. Histologie de la sclerose en plaques. Gazette des hopitaux, Paris, 1868; 41: 554–555.
  2. Poser C (1994). “The dissemination of multiple sclerosis: a Viking saga? A historical essay”. Ann. Neurol. 36 Suppl 2: S231–43. PMID 7998792.
  3. Firth, D (1948). The Case of August D`Esté. Cambridge: Cambridge University Press.

Template:WH Template:WS

Classification

Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1]; Associate Editor(s)-in-Chief: Fahimeh Shojaei, M.D.

Overview

Multiple sclerosis may be classified into four groups according to the clinical course of the disease. This includes relapsing-remitting, secondary-progressive, primary-progressive, and progressive-relapsing.

Classification

Subtypes Explanation
Relapsing remitting
Secondary progressive
  • Patient with long term RRMS can switch to secondary relapsing multiple sclerosis (SPMS) when the neurological symptoms progressively worsen between the attacks
Primary progressive
Progressive relapsing
  • Progressive relapsing multiple sclerosis (PRMS) is defined by progression of disease from the beginning with acute attack episodes

Other new multiple sclerosis subclasses

References

  1. Lublin FD; Reingold SC. Defining the clinical course of multiple sclerosis: results of an international survey. National Multiple Sclerosis Society (USA) Advisory Committee on Clinical Trials of New Agents in Multiple Sclerosis. Neurology 1996 Apr;46(4):907-11. PMID 8780061
  2. 2.0 2.1 2.2 Lublin FD, Reingold SC, Cohen JA, Cutter GR, Sørensen PS, Thompson AJ, Wolinsky JS, Balcer LJ, Banwell B, Barkhof F, Bebo B, Calabresi PA, Clanet M, Comi G, Fox RJ, Freedman MS, Goodman AD, Inglese M, Kappos L, Kieseier BC, Lincoln JA, Lubetzki C, Miller AE, Montalban X, O’Connor PW, Petkau J, Pozzilli C, Rudick RA, Sormani MP, Stüve O, Waubant E, Polman CH (2014). “Defining the clinical course of multiple sclerosis: the 2013 revisions”. Neurology. 83 (3): 278–86. doi:10.1212/WNL.0000000000000560. PMC 4117366. PMID 24871874.
  3. Katz Sand I (2015). “Classification, diagnosis, and differential diagnosis of multiple sclerosis”. Curr. Opin. Neurol. 28 (3): 193–205. doi:10.1097/WCO.0000000000000206. PMID 25887774.

Template:WH Template:WS

Pathophysiology

Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1]; Associate Editor(s)-in-Chief: Fahimeh Shojaei, M.D.,

Overview

Multiple sclerosis is a disease of the central nervous system and it’s known to be multi factorial. Whatever the trigger is, it will lead to an acquired immune response followed by inflammatory reactions. These reactions lead to secretion of cytokines in the CNS parenchyma and activation of resident microglia. Microglia cells activate astrocytes to release more inflammatory cytokines, leading to recruitment and infiltration of circulatory leukocytes. This burst events cause destruction of myelin sheath and forms focal sclerotic white matter plaques, which are characteristic of multiple sclerotic disease. There is some evidence proving genetic involvement in onset of MS so that it increases the risk of developing MS from 0.1% in general population to 3% in those who have siblings with MS and 25% in those with a monozygote twin affected. Based on studies performed on post mortem brain tissue of patients with multiple sclerosis, there are four types of white matter lesion pathology. Damage to myelin sheath is prominent in type 1 and 2 while type 3 and 4 characteristic is dying oligodendrocytes. the etiology of oligodendrocytes death known to be multifactorial or followed by hypoxia, mitochondrial dysfunction and macrophages.

Pathophysiology

Physiology

  • This structure leads to fast traveling of electrical impulses.

Pathogenesis

Genetics

  • There is some evidence proving genetic involvement in onset of MS so that it increases the risk of developing MS from 0.1% in general population to 3% in those who have siblings with MS and 25% in those with a monozygote twin affected.[26]
  • HLA alleles seems to have a huge relationship with MS susceptibility.[27]

Microscopic Pathology

Based on studies performed on post mortem brain tissue of patients with multiple sclerosis, there are four types of white matter lesion pathology:[28][8]

NOTE: Damage to myelin sheath is prominent in type 1 and 2 while type 3 and 4 characteristic is dying oligodendrocytes.[8][30] the etiology of oligodendrocytes death known to be multifactorial or followed by hypoxia, mitochondrial dysfunction and macrophages.[31][32]

Photomicrograph of a demyelinating MS-Lesion. Immunohistochemical staining for CD68 highlights numerous macrophages (brown) . Original Magnification 10x Source: Librepathology
Photomicrograph of a demyelinating MS-Lesion. Klüver-Barerra-Stain. Original Magnification 10x Source: Librepathology

References

  1. Mattle, Heinrich (2017). Fundamentals of neurology : an illustrated guide. Stuttgart New York: Thieme. ISBN 9783131364524.
  2. Fiorini A, Koudriavtseva T, Bucaj E, Coccia R, Foppoli C, Giorgi A, Schininà ME, Di Domenico F, De Marco F, Perluigi M (2013). “Involvement of oxidative stress in occurrence of relapses in multiple sclerosis: the spectrum of oxidatively modified serum proteins detected by proteomics and redox proteomics analysis”. PLoS ONE. 8 (6): e65184. doi:10.1371/journal.pone.0065184. PMC 3676399. PMID 23762311.
  3. John GR, Lee SC, Song X, Rivieccio M, Brosnan CF (2005). “IL-1-regulated responses in astrocytes: relevance to injury and recovery”. Glia. 49 (2): 161–76. doi:10.1002/glia.20109. PMID 15472994.
  4. Kawakami N, Nägerl UV, Odoardi F, Bonhoeffer T, Wekerle H, Flügel A (2005). “Live imaging of effector cell trafficking and autoantigen recognition within the unfolding autoimmune encephalomyelitis lesion”. J. Exp. Med. 201 (11): 1805–14. doi:10.1084/jem.20050011. PMC 2213265. PMID 15939794.
  5. Sofroniew MV (2015). “Astrocyte barriers to neurotoxic inflammation”. Nat. Rev. Neurosci. 16 (5): 249–63. doi:10.1038/nrn3898. PMC 5253239. PMID 25891508.
  6. McCarthy DP, Richards MH, Miller SD (2012). “Mouse models of multiple sclerosis: experimental autoimmune encephalomyelitis and Theiler’s virus-induced demyelinating disease”. Methods Mol. Biol. 900: 381–401. doi:10.1007/978-1-60761-720-4_19. PMC 3583382. PMID 22933080.
  7. Pirko I, Johnson AJ (2008). “Neuroimaging of demyelination and remyelination models”. Curr. Top. Microbiol. Immunol. 318: 241–66. PMID 18219821.
  8. 8.0 8.1 8.2 Mallucci G, Peruzzotti-Jametti L, Bernstock JD, Pluchino S (2015). “The role of immune cells, glia and neurons in white and gray matter pathology in multiple sclerosis”. Prog. Neurobiol. 127-128: 1–22. doi:10.1016/j.pneurobio.2015.02.003. PMC 4578232. PMID 25802011.
  9. Katz Sand I (2015). “Classification, diagnosis, and differential diagnosis of multiple sclerosis”. Curr. Opin. Neurol. 28 (3): 193–205. doi:10.1097/WCO.0000000000000206. PMID 25887774.
  10. Invalid <ref> tag; no text was provided for refs named pmid25665031
  11. Silver NC, Tofts PS, Symms MR, Barker GJ, Thompson AJ, Miller DH (2001). “Quantitative contrast-enhanced magnetic resonance imaging to evaluate blood-brain barrier integrity in multiple sclerosis: a preliminary study”. Mult. Scler. 7 (2): 75–82. doi:10.1177/135245850100700201. PMID 11424635.
  12. van Horssen J, Singh S, van der Pol S, Kipp M, Lim JL, Peferoen L, Gerritsen W, Kooi EJ, Witte ME, Geurts JJ, de Vries HE, Peferoen-Baert R, van den Elsen PJ, van der Valk P, Amor S (2012). “Clusters of activated microglia in normal-appearing white matter show signs of innate immune activation”. J Neuroinflammation. 9: 156. doi:10.1186/1742-2094-9-156. PMC 3411485. PMID 22747960.
  13. Johnson AJ, Suidan GL, McDole J, Pirko I (2007). “The CD8 T cell in multiple sclerosis: suppressor cell or mediator of neuropathology?”. Int. Rev. Neurobiol. 79: 73–97. doi:10.1016/S0074-7742(07)79004-9. PMID 17531838.
  14. Hauser SL, Waubant E, Arnold DL, Vollmer T, Antel J, Fox RJ, Bar-Or A, Panzara M, Sarkar N, Agarwal S, Langer-Gould A, Smith CH (2008). “B-cell depletion with rituximab in relapsing-remitting multiple sclerosis”. N. Engl. J. Med. 358 (7): 676–88. doi:10.1056/NEJMoa0706383. PMID 18272891.
  15. 15.0 15.1 Kutzelnigg A, Lucchinetti CF, Stadelmann C, Brück W, Rauschka H, Bergmann M, Schmidbauer M, Parisi JE, Lassmann H (2005). “Cortical demyelination and diffuse white matter injury in multiple sclerosis”. Brain. 128 (Pt 11): 2705–12. doi:10.1093/brain/awh641. PMID 16230320.
  16. De Stefano N, Matthews PM, Filippi M, Agosta F, De Luca M, Bartolozzi ML, Guidi L, Ghezzi A, Montanari E, Cifelli A, Federico A, Smith SM (2003). “Evidence of early cortical atrophy in MS: relevance to white matter changes and disability”. Neurology. 60 (7): 1157–62. PMID 12682324.
  17. Dehmeshki J, Chard DT, Leary SM, Watt HC, Silver NC, Tofts PS, Thompson AJ, Miller DH (2003). “The normal appearing grey matter in primary progressive multiple sclerosis: a magnetisation transfer imaging study”. J. Neurol. 250 (1): 67–74. doi:10.1007/s00415-003-0955-x. PMID 12527995.
  18. Martínez-Lapiscina EH, Ayuso T, Lacruz F, Gurtubay IG, Soriano G, Otano M, Bujanda M, Bacaicoa MC (2013). “Cortico-juxtacortical involvement increases risk of epileptic seizures in multiple sclerosis”. Acta Neurol. Scand. 128 (1): 24–31. doi:10.1111/ane.12064. PMID 23289848.
  19. Haider L, Simeonidou C, Steinberger G, Hametner S, Grigoriadis N, Deretzi G, Kovacs GG, Kutzelnigg A, Lassmann H, Frischer JM (2014). “Multiple sclerosis deep grey matter: the relation between demyelination, neurodegeneration, inflammation and iron”. J. Neurol. Neurosurg. Psychiatry. 85 (12): 1386–95. doi:10.1136/jnnp-2014-307712. PMC 4251183. PMID 24899728.
  20. Lucchinetti CF, Popescu BF, Bunyan RF, Moll NM, Roemer SF, Lassmann H, Brück W, Parisi JE, Scheithauer BW, Giannini C, Weigand SD, Mandrekar J, Ransohoff RM (2011). “Inflammatory cortical demyelination in early multiple sclerosis”. N. Engl. J. Med. 365 (23): 2188–97. doi:10.1056/NEJMoa1100648. PMC 3282172. PMID 22150037.
  21. 21.0 21.1 Bramow S, Frischer JM, Lassmann H, Koch-Henriksen N, Lucchinetti CF, Sørensen PS, Laursen H (2010). “Demyelination versus remyelination in progressive multiple sclerosis”. Brain. 133 (10): 2983–98. doi:10.1093/brain/awq250. PMID 20855416.
  22. Kuhlmann T, Miron V, Cui Q, Cuo Q, Wegner C, Antel J, Brück W (2008). “Differentiation block of oligodendroglial progenitor cells as a cause for remyelination failure in chronic multiple sclerosis”. Brain. 131 (Pt 7): 1749–58. doi:10.1093/brain/awn096. PMID 18515322.
  23. Patrikios P, Stadelmann C, Kutzelnigg A, Rauschka H, Schmidbauer M, Laursen H, Sorensen PS, Brück W, Lucchinetti C, Lassmann H (2006). “Remyelination is extensive in a subset of multiple sclerosis patients”. Brain. 129 (Pt 12): 3165–72. doi:10.1093/brain/awl217. PMID 16921173.
  24. Bin JM, Rajasekharan S, Kuhlmann T, Hanes I, Marcal N, Han D, Rodrigues SP, Leong SY, Newcombe J, Antel JP, Kennedy TE (2013). “Full-length and fragmented netrin-1 in multiple sclerosis plaques are inhibitors of oligodendrocyte precursor cell migration”. Am. J. Pathol. 183 (3): 673–80. doi:10.1016/j.ajpath.2013.06.004. PMID 23831296.
  25. Franklin RJ, Gallo V (2014). “The translational biology of remyelination: past, present, and future”. Glia. 62 (11): 1905–15. doi:10.1002/glia.22622. PMID 24446279.
  26. Dessa Sadovnick A (July 2002). “The genetics of multiple sclerosis”. Clin Neurol Neurosurg. 104 (3): 199–202. PMID 12127654.
  27. Ramagopalan SV, Dyment DA (March 2011). “What is Next for the Genetics of Multiple Sclerosis?”. Autoimmune Dis. 2011: 519450. doi:10.4061/2011/519450. PMC 3085300. PMID 21541245.
  28. Kutzelnigg A, Lassmann H (2014). “Pathology of multiple sclerosis and related inflammatory demyelinating diseases”. Handb Clin Neurol. 122: 15–58. doi:10.1016/B978-0-444-52001-2.00002-9. PMID 24507512.
  29. Reynolds R, Roncaroli F, Nicholas R, Radotra B, Gveric D, Howell O (2011). “The neuropathological basis of clinical progression in multiple sclerosis”. Acta Neuropathol. 122 (2): 155–70. doi:10.1007/s00401-011-0840-0. PMID 21626034.
  30. Lucchinetti C, Brück W, Parisi J, Scheithauer B, Rodriguez M, Lassmann H (2000). “Heterogeneity of multiple sclerosis lesions: implications for the pathogenesis of demyelination”. Ann. Neurol. 47 (6): 707–17. PMID 10852536.
  31. Lassmann H, Brück W, Lucchinetti C (2001). “Heterogeneity of multiple sclerosis pathogenesis: implications for diagnosis and therapy”. Trends Mol Med. 7 (3): 115–21. PMID 11286782.
  32. Ziabreva I, Campbell G, Rist J, Zambonin J, Rorbach J, Wydro MM, Lassmann H, Franklin RJ, Mahad D (2010). “Injury and differentiation following inhibition of mitochondrial respiratory chain complex IV in rat oligodendrocytes”. Glia. 58 (15): 1827–37. doi:10.1002/glia.21052. PMC 3580049. PMID 20665559.

Template:WH Template:WS

Causes

Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1]; Associate Editor(s)-in-Chief: Fahimeh Shojaei, M.D.

Overview

Multiple sclerosis may be caused by different categories of causes include: Autoimmunity, genetic, infectious and degeneration.

Causes

Common Causes

Common causes of multiple sclerosis may include:

  • Degeneration:
    • In a progressive form of MS, axonal degeneration and cortical atrophy are more prominent rather than contrast- enhancing lesions.[8]
    • Therefore, degeneration is suggested as an independent cause in pathology of multiple sclerosis.[9]

References

  1. Compston A, Coles A (2008). “Multiple sclerosis”. Lancet. 372 (9648): 1502–17. doi:10.1016/S0140-6736(08)61620-7. PMID 18970977.
  2. Korn T (2008). “Pathophysiology of multiple sclerosis”. J. Neurol. 255 Suppl 6: 2–6. doi:10.1007/s00415-008-6001-2. PMID 19300953.
  3. Pette M, Fujita K, Kitze B, Whitaker JN, Albert E, Kappos L, Wekerle H (1990). “Myelin basic protein-specific T lymphocyte lines from MS patients and healthy individuals”. Neurology. 40 (11): 1770–6. PMID 1700336.
  4. Bielekova B, Goodwin B, Richert N, Cortese I, Kondo T, Afshar G, Gran B, Eaton J, Antel J, Frank JA, McFarland HF, Martin R (2000). “Encephalitogenic potential of the myelin basic protein peptide (amino acids 83-99) in multiple sclerosis: results of a phase II clinical trial with an altered peptide ligand”. Nat. Med. 6 (10): 1167–75. doi:10.1038/80516. PMID 11017150.
  5. Sriram S, Mitchell W, Stratton C (1998). “Multiple sclerosis associated with Chlamydia pneumoniae infection of the CNS”. Neurology. 50 (2): 571–2. PMID 9484408.
  6. Soldan SS, Jacobson S (2001). “Role of viruses in etiology and pathogenesis of multiple sclerosis”. Adv. Virus Res. 56: 517–55. PMID 11450311.
  7. Mechelli R, Manzari C, Policano C, Annese A, Picardi E, Umeton R, Fornasiero A, D’Erchia AM, Buscarinu MC, Agliardi C, Annibali V, Serafini B, Rosicarelli B, Romano S, Angelini DF, Ricigliano VA, Buttari F, Battistini L, Centonze D, Guerini FR, D’Alfonso S, Pesole G, Salvetti M, Ristori G (2015). “Epstein-Barr virus genetic variants are associated with multiple sclerosis”. Neurology. 84 (13): 1362–8. doi:10.1212/WNL.0000000000001420. PMC 4388746. PMID 25740864.
  8. Friese MA, Schattling B, Fugger L (2014). “Mechanisms of neurodegeneration and axonal dysfunction in multiple sclerosis”. Nat Rev Neurol. 10 (4): 225–38. doi:10.1038/nrneurol.2014.37. PMID 24638138.
  9. Kutzelnigg A, Lucchinetti CF, Stadelmann C, Brück W, Rauschka H, Bergmann M, Schmidbauer M, Parisi JE, Lassmann H (2005). “Cortical demyelination and diffuse white matter injury in multiple sclerosis”. Brain. 128 (Pt 11): 2705–12. doi:10.1093/brain/awh641. PMID 16230320.

Template:WH Template:WS

Differentiating Multiple sclerosis from other Diseases

Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1]; Associate Editor(s)-in-Chief: Fahimeh Shojaei, M.D.

Overview

Multiple sclerosis must be differentiated from other diseases that can mimic this disease clinically or radiologically such as systemic lupus erythematosis, Sjögren’s syndrome, vasculitis, neuro-behçet’s disease, sarcoidosis, antiphospholipid (Hughes) syndrome , susac syndrome, lyme disease, syphilis, HTLV-1 infection, HIV-Related Disorders of the CNS, migraine, cerebral autosomal dominant arteriopathy with subcortical infarcts and leukoencephalopathy, leber’s hereditary optic neuropathy, vitamin B12 deficiency, metachromatic leukodystrophy, Fabry’s disease, Krabbe’s disease, adrenoleukodystrophy, mitochondrial encephalopathy epilepsy lactic acidosis and stroke like episode, stroke, primary CNS lymphoma , and dural arteriovenous fistula and true malformations.

Differentiating multiple sclerosis from other diseases

Multiple sclerosis must be differentiated from other diseases that can mimic this disease clinically or radiologically such as:

Inflammatory/autoimmune conditions:

Infections:

Metabolic and Genetic/Heriditary Disorders:

  1. Metachromatic leukodystrophy: MLD is an autosomal recessive lysosomal storage disease that leads to accumulation of galactosyl sulfatide.
  2. Fabry’s disease: X-linked disease with impaired activity of a-galactosidase leading to accommodation of globotriaosylceramide in many organs including ganglion cells of the autonomic nervous system.
  3. Krabbe’s disease: Autosomal recessive disease with impaired activity of galactocerebrosidase leading to destruction of CNS and PNS myelin and axonal degeneration.

CNS lymphoma

Primary CNS lymphoma is mostly diffuse large B-cell lymphoma (DLBCL). These patients more commonly present with neurological manifestation rather than B symptoms. In MRI evaluation, because of high cell count and scant cytoplasm lesions become isotense to hypointense on T2. In CSF analysis, there are increased number of WBC and proteins, low levels of glucose and positive cytology for cells with enlarged nucleus and course chromatin.

spinal diseases

Dural arteriovenous fistula and true malformations can be mistaken with MS since they can all cause thoracic myelopathy.

References

Template:WH Template:WS

Epidemiology and Demographics

Editor-In-Chief: C. Michael Gibson, M.S., M.D. [2]; Associate Editor(s)-in-Chief: Fahimeh Shojaei, M.D.

Overview

The majority of multiple sclerosis cases are reported in northern Europe, continental North America, and Australasia, which is about one of every 1000 citizens. Factors including sunlight exposure, climate, diet, toxins, genetic factors, geomagnetism, childhood environmental factors, and infections have been proved to cause the differences in MS prevalence. MS is at least two times more common among women than men. The onset of symptoms is mostly between the age of fifteen to forty years, rarely before age fifteen or after age sixty.

Epidemiology and Demographics

Incidence

  • The incidence of multiple sclerosis is approximately 200 new cases per week in united state.

Prevalence

  • The prevalence of MS varies among countries. according to some studies MS occurs mostly in Caucasians while it is rare in the Native American tribes of North America, Australian Aborigines and the Māori of New Zealand.
  • Among countries Scotland seems to have the highest rate of MS in the world.[1]
  • We can conclude that due to genetic susceptibility, lifestyle and different culture, the development of this disease is not equal in various regions.

Case-fatality rate/Mortality rate

Age

  • The onset of symptoms is mostly between the age of fifteen to forty years, rarely before age fifteen or after age sixty.

Race

  • MS prevalence is lower in African Americans, Mexicans, Japanese, Chinese and Filipinos people rather than white men.[2]

Gender

  • Autoimmune disorders such as MS is at least two times more common among women than men but this difference will disappear after the age of 50 and in children reach three females for each male.

Region

  • The majority of multiple sclerosis cases are reported in northern Europe, continental North America, and Australasia, which is about one of every 1000 citizens while there is a lower frequency of people suffering from Multiple Sclerosis among citizens of the Arabian Peninsula, Asia, and continental South America. In addition, in sub-Saharan Africa, MS is extremely rare.[3]
  • Factors including sunlight exposure, climate, diet, toxins, genetic factors, geomagnetism, Childhood environmental factors and infections have been proved to cause this differences in MS prevalence.
  • Several studies demonstrated that if immigration occurs before the age of fifteen, the migrant’s susceptibility to MS will be equal to that region’s native people, But if migration occurs after the age of fifteen, the migrant’s susceptibility will remain equal to his home country.[4]

It is important to say that some studies on related diseases have shown that some diseases which were formerly considered MS cases are not MS at all. all the studies before 2004 can be affected because of inability to distinguish MS and Devic’s disease (NMO).[5]

Data from World Health Organization Estimated Deaths 2012 Vector map from BlankMap-World6, compact.svg by Canuckguy et al [1]


References

  1. Rothwell PM, Charlton D (1998). “High incidence and prevalence of multiple sclerosis in south east Scotland: evidence of a genetic predisposition”. J. Neurol. Neurosurg. Psychiatr. 64 (6): 730–5. PMID 9647300.
  2. Kurtzke JF, Beebe GW, Norman JE (September 1979). “Epidemiology of multiple sclerosis in U.S. veterans: 1. Race, sex, and geographic distribution”. Neurology. 29 (9 Pt 1): 1228–35. PMID 573402.
  3. Epidemiology and multiple sclerosis. a personal review
  4. Marrie, RA. Environmental risk factors in multiple sclerosis etiology. Lancet Neurol. 2004 Dec;3(12):709-18. Review. PMID 15556803
  5. Weinshenker B (2005). “Western vs optic-spinal MS: two diseases, one treatment?”. Neurology. 64 (4): 594–5. PMID 15728277.

Template:WH Template:WS

Risk Factors

Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1]; Associate Editor(s)-in-Chief: Fahimeh Shojaei, M.D.,

Overview

Common risk factors in the development of multiple sclerosis are smoking, genetic, ethnic, infection, low vitamin D, and stress. Less common risk factors in the development of multiple sclerosis include African Americans, Mexicans, Japanese, Chinese and Filipinos race and Epstein-Barr virus.

Risk Factors

Common Risk Factors

Less Common Risk Factors

References

  1. Riise T, Nortvedt MW, Ascherio A (October 2003). “Smoking is a risk factor for multiple sclerosis”. Neurology. 61 (8): 1122–4. PMID 14581676.
  2. Hernán MA, Olek MJ, Ascherio A (July 2001). “Cigarette smoking and incidence of multiple sclerosis”. Am. J. Epidemiol. 154 (1): 69–74. PMID 11427406.
  3. Robertson NP, Fraser M, Deans J, Clayton D, Walker N, Compston DA (April 1996). “Age-adjusted recurrence risks for relatives of patients with multiple sclerosis”. Brain. 119 ( Pt 2): 449–55. PMID 8800940.
  4. Sadovnick AD, Baird PA, Ward RH (March 1988). “Multiple sclerosis: updated risks for relatives”. Am. J. Med. Genet. 29 (3): 533–41. doi:10.1002/ajmg.1320290310. PMID 3376997.
  5. Orton SM, Herrera BM, Yee IM, Valdar W, Ramagopalan SV, Sadovnick AD, Ebers GC (November 2006). “Sex ratio of multiple sclerosis in Canada: a longitudinal study”. Lancet Neurol. 5 (11): 932–6. doi:10.1016/S1474-4422(06)70581-6. PMID 17052660.
  6. Whitacre CC (September 2001). “Sex differences in autoimmune disease”. Nat. Immunol. 2 (9): 777–80. doi:10.1038/ni0901-777. PMID 11526384.
  7. van der Mei IA, Ponsonby AL, Dwyer T, Blizzard L, Simmons R, Taylor BV, Butzkueven H, Kilpatrick T (August 2003). “Past exposure to sun, skin phenotype, and risk of multiple sclerosis: case-control study”. BMJ. 327 (7410): 316. doi:10.1136/bmj.327.7410.316. PMC 169645. PMID 12907484.
  8. Munger KL, Zhang SM, O’Reilly E, Hernán MA, Olek MJ, Willett WC, Ascherio A (January 2004). “Vitamin D intake and incidence of multiple sclerosis”. Neurology. 62 (1): 60–5. PMID 14718698.
  9. Coo H, Aronson KJ (2004). “A systematic review of several potential non-genetic risk factors for multiple sclerosis”. Neuroepidemiology. 23 (1–2): 1–12. doi:10.1159/000073969. PMID 14739563.
  10. Goodin DS, Ebers GC, Johnson KP, Rodriguez M, Sibley WA, Wolinsky JS (June 1999). “The relationship of MS to physical trauma and psychological stress: report of the Therapeutics and Technology Assessment Subcommittee of the American Academy of Neurology”. Neurology. 52 (9): 1737–45. PMID 10371517.
  11. Kurtzke JF, Beebe GW, Norman JE (September 1979). “Epidemiology of multiple sclerosis in U.S. veterans: 1. Race, sex, and geographic distribution”. Neurology. 29 (9 Pt 1): 1228–35. PMID 573402.
  12. Sundström P, Juto P, Wadell G, Hallmans G, Svenningsson A, Nyström L, Dillner J, Forsgren L (June 2004). “An altered immune response to Epstein-Barr virus in multiple sclerosis: a prospective study”. Neurology. 62 (12): 2277–82. PMID 15210894.
  13. Levin LI, Munger KL, Rubertone MV, Peck CA, Lennette ET, Spiegelman D, Ascherio A (May 2005). “Temporal relationship between elevation of epstein-barr virus antibody titers and initial onset of neurological symptoms in multiple sclerosis”. JAMA. 293 (20): 2496–500. doi:10.1001/jama.293.20.2496. PMID 15914750.

Template:WH Template:WS

Screening

Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1]; Associate Editor(s)-in-Chief: Fahimeh Shojaei, M.D.

Overview

There is insufficient evidence to recommend routine screening for multiple sclerosis.

Screening

There is insufficient evidence to recommend routine screening for multiple sclerosis.

References

Template:WH Template:WS

Natural History, Complications and Prognosis

Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1]; Associate Editor(s)-in-Chief: Fahimeh Shojaei, M.D.

Overview

Multiple sclerosis usually start between age of fifteen to forty years, rarely before age fifteen or after age sixty with symptoms such as optic neuritis, diplopia, sensory or motor loss, vertigo and balance problems. It may be classified into four groups according to clinical course of the disease including relapsing-remitting, secondary-progressive, primary-progressive, and progressive-relapsing. Complications that can develop as a result of multiple sclerosis are: medication complication, Fatigue, mood problems, Spasticity, Bowel and bladder dysfunction, Cognitive impairment, Heat sensitivity., Incoordination, Pain, Sexual dysfunction, Sleep disorders, vertigo, visual loss. there are some factors associated with a particularly poor prognosis among patients with multiple sclerosis such as: Relapsing versus progressive disease, early symptoms, Demographics, Sex, Smoking.

Natural History, Complications, and Prognosis

Natural History

Complications

Complications that can develop as a result of mutiple sclerosis include:

  • Fatigue: Fatigue is seen in almost 80% of MS patients. They commonly feel exhausted and out of energy. We can see fatigue exacerbation before acute attacks in MS and for a while after that.[18]
  • Vertigo: Benign positional paroxysmal vertigo is the most common cause of vertigo in an MS patient. In the course of the disease about 30-50% of patients experience this symptom.[15]

Prognosis

There are some factors associated with a particularly poor prognosis among patients with multiple sclerosis. However, we can’t surly say what is the prognosis of MS patients.[30]

  • Smoking: Transition of RRMS to SPMS can be accelerated with smoking.[39]
  • Lipid specific immunoglobulin level: Lipid specific immunoglobulin level in CSF can predict long term outcomes of MS disease.[40]

References

  1. Weinshenker BG, Bass B, Rice GP, Noseworthy J, Carriere W, Baskerville J, Ebers GC (February 1989). “The natural history of multiple sclerosis: a geographically based study. I. Clinical course and disability”. Brain. 112 ( Pt 1): 133–46. PMID 2917275.
  2. Lublin FD, Reingold SC (April 1996). “Defining the clinical course of multiple sclerosis: results of an international survey. National Multiple Sclerosis Society (USA) Advisory Committee on Clinical Trials of New Agents in Multiple Sclerosis”. Neurology. 46 (4): 907–11. PMID 8780061.
  3. 3.0 3.1 Balcer LJ (March 2006). “Clinical practice. Optic neuritis”. N. Engl. J. Med. 354 (12): 1273–80. doi:10.1056/NEJMcp053247. PMID 16554529.
  4. Čarnická Z, Kollár B, Šiarnik P, Krížová L, Klobučníková K, Turčáni P (April 2015). “Sleep disorders in patients with multiple sclerosis”. J Clin Sleep Med. 11 (5): 553–7. doi:10.5664/jcsm.4702. PMC 4410929. PMID 25700869.
  5. 5.0 5.1 Sadovnick AD, Remick RA, Allen J, Swartz E, Yee IM, Eisen K, Farquhar R, Hashimoto SA, Hooge J, Kastrukoff LF, Morrison W, Nelson J, Oger J, Paty DW (March 1996). “Depression and multiple sclerosis”. Neurology. 46 (3): 628–32. PMID 8618657.
  6. 6.0 6.1 Boissy AR, Cohen JA (September 2007). “Multiple sclerosis symptom management”. Expert Rev Neurother. 7 (9): 1213–22. doi:10.1586/14737175.7.9.1213. PMID 17868019.
  7. 7.0 7.1 DasGupta R, Fowler CJ (2003). “Bladder, bowel and sexual dysfunction in multiple sclerosis: management strategies”. Drugs. 63 (2): 153–66. PMID 12515563.
  8. 8.0 8.1 Achiron A, Barak Y (April 2003). “Cognitive impairment in probable multiple sclerosis”. J. Neurol. Neurosurg. Psychiatry. 74 (4): 443–6. PMC 1738365. PMID 12640060.
  9. Frohman EM, Frohman TC, Zee DS, McColl R, Galetta S (February 2005). “The neuro-ophthalmology of multiple sclerosis”. Lancet Neurol. 4 (2): 111–21. doi:10.1016/S1474-4422(05)00992-0. PMID 15664543.
  10. 10.0 10.1 Selhorst JB, Saul RF (June 1995). “Uhthoff and his symptom”. J Neuroophthalmol. 15 (2): 63–9. PMID 7550931.
  11. 11.0 11.1 Rinker JR, Salter AR, Walker H, Amara A, Meador W, Cutter GR (January 2015). “Prevalence and characteristics of tremor in the NARCOMS multiple sclerosis registry: a cross-sectional survey”. BMJ Open. 5 (1): e006714. doi:10.1136/bmjopen-2014-006714. PMC 4289717. PMID 25573524.
  12. 12.0 12.1 Drulovic J, Basic-Kes V, Grgic S, Vojinovic S, Dincic E, Toncev G, Kezic MG, Kisic-Tepavcevic D, Dujmovic I, Mesaros S, Miletic-Drakulic S, Pekmezovic T (August 2015). “The Prevalence of Pain in Adults with Multiple Sclerosis: A Multicenter Cross-Sectional Survey”. Pain Med. 16 (8): 1597–602. doi:10.1111/pme.12731. PMID 26087108.
  13. 13.0 13.1 Lew-Starowicz M, Gianotten WL (2015). “Sexual dysfunction in patients with multiple sclerosis”. Handb Clin Neurol. 130: 357–70. doi:10.1016/B978-0-444-63247-0.00020-1. PMID 26003254.
  14. 14.0 14.1 Manconi M, Rocca MA, Ferini-Strambi L, Tortorella P, Agosta F, Comi G, Filippi M (January 2008). “Restless legs syndrome is a common finding in multiple sclerosis and correlates with cervical cord damage”. Mult. Scler. 14 (1): 86–93. doi:10.1177/1352458507080734. PMID 17942519.
  15. 15.0 15.1 Frohman EM, Zhang H, Dewey RB, Hawker KS, Racke MK, Frohman TC (November 2000). “Vertigo in MS: utility of positional and particle repositioning maneuvers”. Neurology. 55 (10): 1566–9. PMID 11094117.
  16. Yamamoto T, Irisa T, Sugioka Y, Sueishi K (November 1997). “Effects of pulse methylprednisolone on bone and marrow tissues: corticosteroid-induced osteonecrosis in rabbits”. Arthritis Rheum. 40 (11): 2055–64. doi:10.1002/1529-0131(199711)40:11&lt;2055::AID-ART19&gt;3.0.CO;2-E. PMID 9365096.
  17. Assouline-Dayan Y, Chang C, Greenspan A, Shoenfeld Y, Gershwin ME (October 2002). “Pathogenesis and natural history of osteonecrosis”. Semin. Arthritis Rheum. 32 (2): 94–124. PMID 12430099.
  18. Krupp L (August 2006). “Fatigue is intrinsic to multiple sclerosis (MS) and is the most commonly reported symptom of the disease”. Mult. Scler. 12 (4): 367–8. doi:10.1191/135248506ms1373ed. PMID 16900749.
  19. Sadovnick AD, Eisen K, Ebers GC, Paty DW (August 1991). “Cause of death in patients attending multiple sclerosis clinics”. Neurology. 41 (8): 1193–6. PMID 1866003.
  20. Stenager EN, Stenager E (December 1992). “Suicide and patients with neurologic diseases. Methodologic problems”. Arch. Neurol. 49 (12): 1296–303. PMID 1449409.
  21. Wintner A, Kim MM, Bechis SK, Kreydin EI (April 2016). “Voiding Dysfunction in Multiple Sclerosis”. Semin Neurol. 36 (2): 219–20. doi:10.1055/s-0036-1582255. PMID 27116728.
  22. Hennessey A, Robertson NP, Swingler R, Compston DA (November 1999). “Urinary, faecal and sexual dysfunction in patients with multiple sclerosis”. J. Neurol. 246 (11): 1027–32. PMID 10631634.
  23. Deloire MS, Salort E, Bonnet M, Arimone Y, Boudineau M, Amieva H, Barroso B, Ouallet JC, Pachai C, Galliaud E, Petry KG, Dousset V, Fabrigoule C, Brochet B (April 2005). “Cognitive impairment as marker of diffuse brain abnormalities in early relapsing remitting multiple sclerosis”. J. Neurol. Neurosurg. Psychiatry. 76 (4): 519–26. doi:10.1136/jnnp.2004.045872. PMC 1739602. PMID 15774439.
  24. Rao SM, Leo GJ, Bernardin L, Unverzagt F (May 1991). “Cognitive dysfunction in multiple sclerosis. I. Frequency, patterns, and prediction”. Neurology. 41 (5): 685–91. PMID 2027484.
  25. Huijbregts SC, Kalkers NF, de Sonneville LM, de Groot V, Reuling IE, Polman CH (July 2004). “Differences in cognitive impairment of relapsing remitting, secondary, and primary progressive MS”. Neurology. 63 (2): 335–9. PMID 15277630.
  26. Foley PL, Vesterinen HM, Laird BJ, Sena ES, Colvin LA, Chandran S, MacLeod MR, Fallon MT (May 2013). “Prevalence and natural history of pain in adults with multiple sclerosis: systematic review and meta-analysis”. Pain. 154 (5): 632–42. doi:10.1016/j.pain.2012.12.002. PMID 23318126.
  27. Zivadinov R, Zorzon M, Bosco A, Bragadin LM, Moretti R, Bonfigli L, Iona LG, Cazzato G (December 1999). “Sexual dysfunction in multiple sclerosis: II. Correlation analysis”. Mult. Scler. 5 (6): 428–31. doi:10.1177/135245859900500i610. PMID 10618700.
  28. Amarenco G, Kerdraon J, Denys P (December 1995). “[Bladder and sphincter disorders in multiple sclerosis. Clinical, urodynamic and neurophysiological study of 225 cases]”. Rev. Neurol. (Paris) (in French). 151 (12): 722–30. PMID 8787103.
  29. Schürks M, Bussfeld P (April 2013). “Multiple sclerosis and restless legs syndrome: a systematic review and meta-analysis”. Eur. J. Neurol. 20 (4): 605–15. doi:10.1111/j.1468-1331.2012.03873.x. PMID 23078359.
  30. Swanton J, Fernando K, Miller D (2014). “Early prognosis of multiple sclerosis”. Handb Clin Neurol. 122: 371–91. doi:10.1016/B978-0-444-52001-2.00015-7. PMID 24507526.
  31. 31.0 31.1 Weinshenker BG (1994). “Natural history of multiple sclerosis”. Ann. Neurol. 36 Suppl: S6–11. PMID 8017890.
  32. Confavreux C, Vukusic S, Moreau T, Adeleine P (November 2000). “Relapses and progression of disability in multiple sclerosis”. N. Engl. J. Med. 343 (20): 1430–8. doi:10.1056/NEJM200011163432001. PMID 11078767.
  33. Tremlett H, Paty D, Devonshire V (January 2006). “Disability progression in multiple sclerosis is slower than previously reported”. Neurology. 66 (2): 172–7. doi:10.1212/01.wnl.0000194259.90286.fe. PMID 16434648.
  34. Confavreux C, Vukusic S (March 2006). “Age at disability milestones in multiple sclerosis”. Brain. 129 (Pt 3): 595–605. doi:10.1093/brain/awh714. PMID 16415309.
  35. Confavreux C, Vukusic S (March 2006). “Natural history of multiple sclerosis: a unifying concept”. Brain. 129 (Pt 3): 606–16. doi:10.1093/brain/awl007. PMID 16415308.
  36. Langer-Gould A, Popat RA, Huang SM, Cobb K, Fontoura P, Gould MK, Nelson LM (December 2006). “Clinical and demographic predictors of long-term disability in patients with relapsing-remitting multiple sclerosis: a systematic review”. Arch. Neurol. 63 (12): 1686–91. doi:10.1001/archneur.63.12.1686. PMID 17172607.
  37. Kremenchutzky M, Rice GP, Baskerville J, Wingerchuk DM, Ebers GC (March 2006). “The natural history of multiple sclerosis: a geographically based study 9: observations on the progressive phase of the disease”. Brain. 129 (Pt 3): 584–94. doi:10.1093/brain/awh721. PMID 16401620.
  38. Cree BA, Khan O, Bourdette D, Goodin DS, Cohen JA, Marrie RA, Glidden D, Weinstock-Guttman B, Reich D, Patterson N, Haines JL, Pericak-Vance M, DeLoa C, Oksenberg JR, Hauser SL (December 2004). “Clinical characteristics of African Americans vs Caucasian Americans with multiple sclerosis”. Neurology. 63 (11): 2039–45. PMID 15596747.
  39. Roudbari SA, Ansar MM, Yousefzad A (July 2013). “Smoking as a risk factor for development of Secondary Progressive Multiple Sclerosis: A study in IRAN, Guilan”. J. Neurol. Sci. 330 (1–2): 52–5. doi:10.1016/j.jns.2013.04.003. PMID 23628463.
  40. Thangarajh M, Gomez-Rial J, Hedström AK, Hillert J, Alvarez-Cermeño JC, Masterman T, Villar LM (November 2008). “Lipid-specific immunoglobulin M in CSF predicts adverse long-term outcome in multiple sclerosis”. Mult. Scler. 14 (9): 1208–13. doi:10.1177/1352458508095729. PMID 18755821.

Template:WH Template:WS

Diagnosis

Diagnosis

Diagnostic study of choice | History and Symptoms | Physical Examination | Laboratory Findings | Electrocardiogram | X-Ray Findings | Echocardiography and Ultrasound | CT-Scan Findings | MRI Findings | Other Imaging Findings | Other Diagnostic Studies

Treatment

Treatment

Medical Therapy | Surgery | Alternative Therapies | Primary Prevention | Secondary Prevention | Tertiary Prevention | Cost-effectiveness of Therapy | Future or Investigational Therapies

Case Studies

Case Studies

Case #1

Related Chapters


Template:Diseases of the nervous system ar:تصلب الأنسجة المتعدد bg:Множествена склероза ca:Esclerosi múltiple cs:Roztroušená skleróza de:Multiple Sklerose el:Πολλαπλή σκλήρυνση eo:Sklerozo multiloka fa:اسکلروز چندگانه id:Sklerosis ganda it:Sclerosi multipla he:טרשת נפוצה hu:Sclerosis multiplex nl:Multiple sclerose no:Multippel sklerose sq:Multiple skleroza sr:Multipla skleroza fi:MS-tauti sv:Multipel skleros


Template:WikiDoc Sources

Looking for the patient version?

Back to the patient-friendly article

© 2026 MyEClinic – IFTM Institut für Telematik in der Medizin GmbH